Abstract
Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 520-531 |
Number of pages | 12 |
Journal | Frontiers in Bioscience - Scholar |
Volume | 4 S |
Issue number | 2 |
DOIs | |
State | Published - Jan 1 2012 |
Keywords
- Cancer therapeutics
- Cellular therapy
- Chimeric antigen receptor
- Lymphoid malignancies
- Review
- T cell therapy
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- General Immunology and Microbiology